AUSTIN, Texas, April 19, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate…
Addition of new therapeutic expert reflects company’s commitment to drug development in hematologyDURHAM, N.C., April 19, 2023 (GLOBE NEWSWIRE) --…
Single and repeat dosing of UNO improves outcomes compared to checkpoint inhibitor monotherapy in the aggressive 4T1 breast cancer model…
SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), announced new preclinical data at…
Data further characterize narazaciclib’s mechanism of action and show its anti-cancer activity comparing favorably to that of FDA-approved CDK 4/6…
BOSTON, MASSACHUSETTS, April 19, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral…
-- The study’s primary objective is to evaluate the safety of Lomecel-B™ in Japan’s elderly population -- -- First-in-human clinical trial…
BEDFORD, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early…
MIAMI, FL, April 19, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines…
Findings from a mouse model of peritoneally disseminated ovarian cancer suggest biweekly dosing regimen for further evaluation in human clinical…